REBECCA KING: Open Payments
NPI 1154027456 · COLORADO SPRINGS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$391 in 19 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $391
Food & beverage: $391
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $76 |
| Astellas Pharma US Inc | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| ViiV Healthcare Company | 1 | $24 |
| Organon LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
Products named: Veozah, REXULTI, Kerendia, JARDIANCE, MOUNJARO, TEZSPIRE, CAPLYTA, APRETUDE.
Industry payments across CO — which companies pay providers there.
